Based on recent data, Recursion Pharmaceuticals, Inc. (RXRX) shows an Average True Range (ATR) of 0.3 and an Enterprise Value of 1.37B. Its average trading volume over the past 3 months is 16.74M, indicating liquidity. These fundamental metrics provide insight into RXRX's underlying financial health and market activity.
| ATR | 0.3 |
| Enterprise Value | 1.37B |
| Avg Vol (3 Months) | 16.74M |
| Avg Vol (10 Days) | 12.94M |
Recursion Pharmaceuticals, Inc. (RXRX) technical indicators as of April 22, 2026: the SMA 20 is -0.07%, SMA 50 at -10.38%, and SMA 200 at -22.56%. The RSI 14 value is 46.4, suggesting its current momentum. These technical analysis signals help assess RXRX's price trends and potential future movements.
| SMA 20 | -0.07% |
| SMA 50 | -10.38% |
| SMA 200 | -22.56% |
| RSI 14 | 46.4 |
Recursion Pharmaceuticals, Inc. (RXRX) stock performance overview as of April 22, 2026: The 52-week high is $7.18 (currently -56.62% below), and the 52-week low is $2.8 (currently 26.51% above). Over the past year, RXRX's performance is -31.25%, compared to the S&P 500's 24.91% change.
| 52-Week High | 7.18 |
| 52-Week High Chg | -56.62% |
| 52-Week Low | 2.8 |
| 52-Week Low Chg | +26.51% |
| S&P 500 52-Week Chg | 24.91% |
According to market data, Recursion Pharmaceuticals, Inc. (RXRX) stock's recent performance metrics show that over the last month, RXRX is -5.98%, with a Year-to-Date (YTD) performance of 7.58%. Over the past year, the stock has seen a -31.25% change. These figures summarize RXRX's price movements across various periods, reflecting its historical returns.
| Period | 1 Week | 1 Month | Quarter | Half Year | 1 Year | YTD |
|---|---|---|---|---|---|---|
| High | 3.9 | 3.9 | 5.24 | 7.18 | 7.18 | 5.24 |
| Low | 3.47 | 2.8 | 2.8 | 2.8 | 2.8 | 2.8 |
| Performance | -8.52% | -5.98% | -24.91% | -31.25% | -31.25% | +7.58% |
According to current financial data, RXRX stock's P/E (TTM) ratio is -2.94, which compares to the S&P 500's P/E of 32.59. The sector median P/E is -1.22. Key valuation ratios for RXRX, including P/S (21.56), P/B (1.67), and P/FCF (-4.25), offer insights into how the company is valued relative to its earnings, sales, book value, and free cash flow.
| Valuation | RXRX | Sector Median | Industry Avg | S&P 500 |
|---|---|---|---|---|
| P/E (TTM) | -2.94 | -1.22 | -5.12 | 32.59 |
| P/S (TTM) | 21.56 | 3.69 | 464.32 | 5.98 |
| P/B (TTM) | 1.67 | 3.88 | 0.66 | 5 |
| P/FCF (TTM) | -4.25 | -0.99 | -455.63 | 34.76 |
© 2026 Stocks Telegraph All rights reserved.
Most stock quote data provided by Financial Modeling Prep